Subscribe to Newsletter
Diagnostics COVID-19, Screening and monitoring, Analytical science

COVID-19 Lessons from Newborn Screening

Early disease detection leads to faster, more effective treatments and improved outcomes. These fundamental goals underpin newborn screening for rare inherited disorders. We can apply the lessons learned from more than a half decade of newborn screening to some of the issues surrounding infectious disease detection – specifically, COVID-19. Today, we undertake the public health mission of saving lives every day for hundreds of thousands of newborns. What can we take from this work to improve our response to the current pandemic?

To answer that question, we must ask another: what are the key issues facing screening in healthcare? One is false results. As laboratorians, the methods we develop must be accepted by public health specialists and the clinicians who order the tests. To be useful in a public health screening environment, a method must have a target of zero false negatives and exceptionally low false positives. Furthermore, it must be able to test large numbers of samples accurately and precisely; it must be affordable to the consumer or payer; and samples collected must be adequate. What makes a sample adequate? It must be:

  • the appropriate biological matrix of the target marker
  • stable enough to meet the logistics of a large patient population
  • accessible and readily available

How can we possibly address all of these needs? Current newborn screening protocols provide an excellent model.

False results are a real issue for any test and their impact is often poorly understood. In clinical chemistry, a false negative or missed case is unacceptable. Without detection, there is no path to early intervention and treatment. Positive results are subject to confirmation through additional screening or diagnostic tests. A true positive is usually confirmed by other information and by a clinical diagnosis; false positives cannot be confirmed and are ultimately categorized as normal.

Our methods have high sensitivity and specificity. For instance, in newborn screening, tandem mass spectrometry replaced other methods because it was more accurate and precise in its measurements for many diseases. In fact, clinicians needed new action plans because a “presumed positive” was so much more likely to be a true positive and thus could be acted on while confirmatory testing was still underway. 

I urge my colleagues to look to the children – in our existing screening models may lie better solutions for COVID-19.

There are many different COVID-19 tests with different rates of “false alarms” – understandable in an emerging disease with only a few months of research history. What matters is that clinicians and public health experts understand the accuracy of each test and communicate it well to patients. Ultimately, every COVID-19 test we have is a step along the path to a diagnosis. The diagnosis is made when we combine initial test results with confirmatory testing and the signs and symptoms of COVID-19. For those of us who develop those tests, our job is to provide the best possible screening and diagnostic tools. Our job is to minimize false results. Our job is to provide data that ultimately lead to better health information and patient care. It’s my hope that, one day soon, we will be able to do for COVID-19 testing what we have achieved with newborn screening. In the meantime, I urge my colleagues to look to the children – in our existing screening models may lie better solutions for COVID-19.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Donald H. Chace

Chief Scientific Officer at Medolac Laboratories, Boulder City, Nevada, USA.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine